EUVIMEDEUVIMED entdecken
Crossref

A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery

Yulong Yan, Jing Shi, Zhenqiao Zheng, Xiaojing Shi, Xubo Zhao

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.115143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Yulong Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Hyaluronic Acid, Doxorubicin, Prodrugs, Nanoparticles. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional nanocarriers often face challenges of insufficient tumor specificity and poor cellular internalization. To overcome these limitations, we developed an all-in-one prodrug nanoplatform based on hyaluronic acid (HA) that synergistically integrates active targeting, pH-responsive charge reversal, and controlled drug release. Doxorubicin (DOX) was covalently conjugated to oxidized HA via a pH-sensitive imine bond, while a charge-reversal polymer (PLL-DMMA) was grafted onto the HA backbone. This design enables CD44-mediated active targeting toward cancer cells. Crucially, the nanoplatform exhibits a smart charge-reversal characteristic: maintaining a negative surface charge (-32.8 mV) at physiological condition (pH 7.4) for extended circulation, while switching to positive (+16.5 mV) in the acidic tumor microenvironment (pH 6.5) to enhance cellular uptake. In vitro studies demonstrated significantly improved internalization in CD44-overexpressing MKN-45 cells compared to SNU-216 cells with low CD44 expression. The release profile showed high stability at pH 7.4 (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidDoxorubicinProdrugsNanoparticlesAntibiotics, AntineoplasticHumansCell Line, TumorHydrogen-Ion ConcentrationHyaluronan ReceptorsDrug LiberationDrug Delivery SystemsPolymersDrug CarriersDelayed-Action PreparationsTumor Microenvironment

Stichwörter der Autor:innen

Drug delivery systemHyaluronic acidProdrug

Substanzen

Hyaluronic AcidDoxorubicinProdrugsHyaluronan ReceptorsPolymersDrug CarriersDelayed-Action PreparationsAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Laboratory Animal Center, Zhengzhou U…
  • College of Chemistry, Zhengzhou University, Zhengzhou 450001, China. Electronic address: shixiaojing@zzu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yan, Y., Shi, J., Zheng, Z., Shi, X., & Zhao, X. (2026). A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115143

Vancouver

Yan Y, Shi J, Zheng Z, Shi X, Zhao X. A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115143

BibTeX
@article{Yan2026,
  author = {Yan, Yulong and Shi, Jing and Zheng, Zhenqiao and Shi, Xiaojing and Zhao, Xubo},
  title = {A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.115143}
}
Kostenlos starten →